MarketVIEW: Cytomegalovirus vaccines

  • June 2012
  • -
  • VacZine Analytics Group Of Assay Advantage Ltd
  • -
  • 60 pages

Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around 50-80% of adults are infected by 40 years of age (US CDC figures) whereas in other parts of the world, especially developing countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues, however, in certain populations with a weakened immune system e.g. HIV, transplants (HSCT) the virus can reactivate can cause disease e.g. pneumonia. CMV infection is also a concern in the neonate after transmission from a pregnant women pre or post partum. Approximately 1 in 150 children is born with a congenital CMV infection and 1 in 750 born with permanent disabilities due to the virus. 

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Cytomegalovirus vaccines (TX + PX approaches) across major Western and emerging markets to 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the level of populations targeted, which in turn are influenced by vaccine mechanism of action and vaccinee serostatus. 

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL 

Table Of Contents

Executive summary
CMV preconception vaccine: available market ($000s) to 2035
CMV transplant vaccine: available market ($000s) to 2035
CMV preconception vaccine: demand (000s doses) to 2035
CMV transplant vaccine: demand (000s doses) to 2035
CMV vaccine: modelling assumptions/rationale
The role of CMV vaccine(s)
Target populations: CMV preconception vaccine
Target populations: CMV transplant vaccine
Target groups by serological risk profile
Pricing: CMV preconception vaccine
Pricing: CMV transplant vaccine
Target product profile: CMV preconception vaccine
Target product profile: CMV transplant vaccine
Key commercial model assumptions: preconception vaccine
Key commercial model assumptions: transplant vaccine
Markets included in the model
Model forecast comparisons: June 2010 v current
CMV vaccines: RandD pipeline
Competitor landscape: overview
Vical/Astellas: TransVax and CyMVectin
GSK: preconception CMV vaccine
Novartis/AlphaVax: alphavirus replicon CMV vaccine
Sanofi Pasteur: CMV gB vaccine
Other vaccine candidates
Vaccine pipeline summary
Estimated launch dates
CMV: review of current epidemiology
Epidemiology: transplants
Epidemiology: congenital CMV infection
Methodology: HSCTs populations (by age and serostatus)
Methodology: solid organ transplant populations (by age and serostatus)
Methodology: preconception vaccine
Preconception vaccine: comparison of “low” versus “high” coverage scenarios
References/bibliography
About VacZine Analytics
Disclaimer
PAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents - Vaccine demand model (MS Excel-based)
Title sheet
Scenarion definitions
GRAND SUMMARY CHARTS
CHARTS VALUE
CHARTS VOLUME
CHARTS VOLUME - HIGH
VALUE SUMMARY
VOLUME SUMMARY
Preconception vaccine - females
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Transplant vaccine - females
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Source material
HSCTs by serostatus
Forecast HSCTs
Forecast HSCTs
Kidney and Liver TX base
Forecast Kidney TX
Forecast liver Tx
SOT by serostatus
Populations
Back page
About VacZine Analytics
Disclaimer

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...

DNA Vaccines: Technologies and Global Markets

DNA Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research study determines the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. High growth and market potential segments of the ...

Detailed I/E report of Carbendazim export analysis

Detailed I/E report of Carbendazim export analysis

  • $ 5 400
  • Industry report
  • July 2014
  • by CCM International Limited

Carbendazim export analysis will help clients indentify export situation of technical and formulations with exclusive research methods, to offer not only the target products' export volume, price, time, ...

Marketview: Rotavirus Vaccines

June 2014 $ 4 495

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.